CD-38 Immunohistochemistry Test in Lahore at Lahore PCR Lab

CD-38 Immunohistochemistry at Lahore PCR Lab

CD-38 Immunohistochemistry (IHC) is a highly specialized pathology investigation performed to detect and quantify the expression of the CD38 glycoprotein on the surface of cells. This diagnostic test is primarily carried out on tissue biopsy specimens, most commonly bone marrow trephine biopsies, lymph node biopsies, or solid tumor tissues. CD38 is a type II transmembrane glycoprotein that plays a multifunctional role as both a receptor and an ectoenzyme involved in cell adhesion, signal transduction, and calcium signaling. In clinical medicine, evaluating CD38 expression is of paramount importance for the diagnosis, classification, and prognostic stratification of hematological malignancies, particularly plasma cell disorders and lymphoid neoplasms.

The test works by utilizing highly specific monoclonal antibodies designed to bind exclusively to the CD38 antigen present in the tissue sample. At Lahore PCR Lab in Lahore, Pakistan, this procedure is executed using advanced automated staining platforms. Once the antibodies bind to the target CD38 proteins, a secondary detection system coupled with a chromogen (typically diaminobenzidine, which produces a brown precipitate) is applied. This visualizes the localized antigen-antibody complexes under a light microscope. A consultant pathologist then analyzes the staining intensity, cellular distribution, and percentage of positive cells to provide a definitive diagnostic assessment.

The clinical importance of CD-38 IHC cannot be overstated. It serves as a cornerstone in the diagnostic workup of plasma cell dyscrasias, such as multiple myeloma, where plasma cells characteristically exhibit strong and uniform CD38 expression. Furthermore, it provides critical prognostic information in chronic lymphocytic leukemia (CLL), where high CD38 expression correlates with a more aggressive clinical course. By identifying the exact cellular lineage and differentiation stage of abnormal cells, CD-38 IHC helps oncologists and hematologists formulate precise, personalized treatment strategies, including the use of targeted monoclonal antibody therapies like daratumumab, which directly target the CD38 molecule.

Clinical Procedure: What to Expect

Patient Preparation

Because CD-38 Immunohistochemistry is a laboratory test performed on a tissue specimen (biopsy or surgical resection), the preparation guidelines depend entirely on whether you are undergoing a new biopsy procedure or if the test is being performed on an existing paraffin-embedded tissue block (archival sample).

• Existing Tissue Block (Paraffin Block/Slides): If your physician has requested the test to be performed on a biopsy sample already collected at another facility, no direct patient preparation is required. You simply need to submit the paraffin block and corresponding pathology slides to Lahore PCR Lab along with the original histopathology report.
• New Bone Marrow or Lymph Node Biopsy: If a new biopsy is required to obtain the tissue, you must follow specific clinical instructions. Inform your doctor about all current medications, especially blood thinners like aspirin, warfarin, clopidogrel, or novel oral anticoagulants, which may need to be temporarily discontinued under medical supervision.
• Fasting Requirements: Fasting is generally not required for a standard local anesthetic biopsy. However, if your biopsy is scheduled under conscious sedation or general anesthesia, you must fast (no food or liquids) for at least 6 to 8 hours prior to the procedure.
• Medical History Documentation: Always provide a complete clinical history, including previous chemotherapy, radiation therapy, or immunotherapy, as these treatments can significantly alter CD38 expression patterns.

During the Procedure

The laboratory phase of CD-38 Immunohistochemistry is a highly controlled, multi-step process conducted by skilled histotechnologists and pathologists at Lahore PCR Lab. The procedure involves the following clinical steps:

• Specimen Processing: The tissue specimen obtained from the patient is fixed in neutral buffered formalin to preserve cellular architecture. It is then dehydrated and embedded in paraffin wax to create a tissue block.
• Microtomy: Ultra-thin sections, measuring approximately 3 to 4 micrometers, are cut from the paraffin block using a precision microtome and mounted onto specialized charged glass slides.
• Antigen Retrieval: The tissue sections undergo deparaffinization and rehydration. Because formalin fixation can mask target antigens, the slides are subjected to heat-induced epitope retrieval (HIER) using specific buffer solutions to expose the CD38 antigenic sites.
• Antibody Incubation: The slides are incubated with a primary anti-CD38 monoclonal antibody. This is followed by incubation with a secondary antibody conjugated with an enzyme complex (such as horseradish peroxidase).
• Chromogenic Visualization: A chromogen substrate is applied, producing a visible colored precipitate at the site of CD38 antigen localization. The slides are counterstained with hematoxylin to visualize cell nuclei, dehydrated, and coverslipped.
• Microscopic Analysis: The pathologist examines the slides under a high-resolution light microscope, assessing the percentage of positive cells, the intensity of staining (weak, moderate, or strong), and the specific localization (membranous or cytoplasmic).

When is a CD-38 Immunohistochemistry Performed?

Suspected Multiple Myeloma

Multiple myeloma is a clonal plasma cell malignancy characterized by the uncontrolled proliferation of abnormal plasma cells in the bone marrow. Patients often present with symptoms such as persistent bone pain (especially in the back or ribs), unexplained fatigue, recurrent infections, and renal dysfunction. Physicians request CD-38 IHC on bone marrow biopsies to confirm the presence of an abnormal plasma cell infiltrate. Because CD38 is highly and uniformly expressed on both normal and neoplastic plasma cells, this marker allows pathologists to clearly identify, quantify, and assess the distribution of plasma cells within the bone marrow microenvironment, establishing a definitive diagnosis.

Prognostic Evaluation in Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia is a clonal malignancy of mature B-lymphocytes. While some CLL patients experience an indolent, slow-growing form of the disease, others exhibit a rapidly progressive course. Symptoms include painless swelling of lymph nodes (lymphadenopathy), night sweats, weight loss, and frequent infections. CD-38 IHC is performed on lymph node or bone marrow biopsies of CLL patients because CD38 expression serves as a vital prognostic marker. Patients with a high percentage of CD38-positive leukemia cells (typically defined as 30% or greater) generally have a more aggressive disease course, shorter treatment-free survival, and may require more intensive therapeutic interventions.

Diagnosis of Plasma Cell Leukemia

Plasma Cell Leukemia (PCL) is a rare and highly aggressive form of plasma cell dyscrasia characterized by a high number of circulating plasma cells in the peripheral blood. Patients present with severe anemia, thrombocytopenia, hepatosplenomegaly, and osteolytic bone lesions. CD-38 IHC is crucial in distinguishing PCL from other lymphoid malignancies and leukemias. The intense, diffuse membranous staining of CD38 on the circulating or marrow-infiltrating cells, combined with other markers like CD138, confirms the plasma cell lineage of the malignant cells, allowing for immediate initiation of aggressive systemic therapy.

Monitoring Anti-CD38 Monoclonal Antibody Therapy

With the advent of targeted immunotherapy, monoclonal antibodies directed against CD38 (such as daratumumab and isatuximab) have become standard treatments for multiple myeloma. Before initiating these therapies, physicians request a baseline CD-38 IHC to confirm target expression on the tumor cells. Additionally, during or after therapy, CD-38 IHC may be performed to monitor treatment response, detect minimal residual disease (MRD), or evaluate for potential antigen escape (downregulation of CD38 expression), which can guide subsequent therapeutic adjustments.

Evaluation of Systemic AL Amyloidosis

Systemic Light Chain (AL) Amyloidosis is a disorder characterized by the extracellular deposition of monoclonal light chain fibrils, leading to progressive organ dysfunction. Patients often present with unexplained proteinuria, congestive heart failure, peripheral neuropathy, or hepatomegaly. The underlying cause is a small, often indolent clone of plasma cells in the bone marrow. CD-38 IHC is performed on bone marrow biopsies to detect and characterize these subtle plasma cell clones, which might otherwise be missed on routine hematoxylin and eosin (H&E) staining, facilitating early diagnosis and treatment to prevent irreversible organ damage.

What Does a CD-38 Immunohistochemistry Detect?

CD-38 Immunohistochemistry is designed to detect, localize, and quantify specific cellular and pathological features within a tissue specimen. The test provides critical diagnostic parameters, including:

• Presence of CD38-positive plasma cells in the bone marrow or lymphoid tissues.
• Percentage of plasma cells relative to the total nucleated cell population.
• Intensity of CD38 expression (graded as weak, moderate, or strong).
• Subcellular localization of the CD38 antigen (typically membranous).
• Distribution pattern of positive cells (diffuse sheets, interstitial clusters, or single scattered cells).
• Co-expression patterns when evaluated alongside other immunohistochemical markers (e.g., CD138, CD19, CD56).
• Presence of clonal restriction (when correlated with kappa and lambda light chain staining).
• Identification of neoplastic plasma cells in extramedullary plasmacytomas.
• Prognostic stratification of Chronic Lymphocytic Leukemia (CLL) cells based on the 30% positivity threshold.
• Detection of minimal residual disease (MRD) in post-treatment bone marrow specimens.
• Presence of CD38 expression on precursor B and T lymphoblasts in acute lymphoblastic leukemia.
• Expression levels on activated T-lymphocytes and natural killer (NK) cells within the tumor microenvironment.
• Differentiation between normal reactive plasma cells and neoplastic plasma cell populations.
• Identification of plasma cell differentiation in B-cell non-Hodgkin lymphomas.
• Assessment of CD38 expression in histiocytic and dendritic cell neoplasms.
• Evaluation of bone marrow biopsy cellularity and architectural preservation.
• Presence of osteolytic microenvironment indicators associated with plasma cell aggregates.
• Baseline target density prior to anti-CD38 monoclonal antibody therapy.
• Post-treatment downregulation or loss of CD38 expression on malignant cells.
• Correlation with cytogenetic and molecular risk profiles in hematological disorders.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand that timely diagnostic results are critical for initiating oncological and hematological treatments. The turnaround time for CD-38 Immunohistochemistry typically ranges from 3 to 5 working days. This timeframe is necessary to ensure rigorous tissue processing, precise automated staining, quality control validation, and a comprehensive microscopic evaluation by our consultant pathologists.

Patients and referring physicians can access diagnostic reports conveniently through multiple digital channels. Once the report is finalized and signed off by the pathologist, an automated SMS notification containing a secure download link is sent to the patient’s registered mobile number. Reports can also be accessed and downloaded directly from the official Lahore PCR Lab online portal. For convenience, physical copies of the reports can be collected from our main diagnostic center in Lahore or delivered via secure courier services upon request.

CD-38 Immunohistochemistry Findings Overview

The following table outlines the typical parameters evaluated during a CD-38 Immunohistochemistry test, comparing normal physiological findings with abnormal pathological states:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Plasma Cell Percentage (Bone Marrow)	Less than 1% to 2% of total nucleated cells.	Greater than 10% (indicative of Multiple Myeloma or Smoldering Myeloma); greater than 60% (highly diagnostic of active Myeloma).
Staining Intensity (Plasma Cells)	Moderate to strong, uniform membranous staining.	Variable or weak staining, occasionally observed in treated cases or specific atypical subclones.
Distribution Pattern	Scattered, isolated single cells throughout the marrow.	Dense clusters, nodular aggregates, or diffuse sheets of plasma cells replacing normal hematopoietic tissue.
CLL Prognostic Marker	Less than 30% of B-lymphocytes expressing CD38.	30% or greater CD38 expression on B-CLL cells (associated with unfavorable prognosis and rapid progression).
Co-expression Profile	CD38+, CD138+, CD19+, CD56- (Normal plasma cells).	CD38+, CD138+, CD19-, CD56+ (Aberrant phenotype typical of neoplastic plasma cells).
Extramedullary Tissue	Absence of abnormal CD38-positive cellular infiltrates.	Dense sheets of CD38-positive cells in soft tissue or bone lesions (suggestive of Plasmacytoma).
Post-Therapy Assessment	Normal baseline expression or complete clearance of clonal cells.	Persistent CD38-positive clonal cells (Minimal Residual Disease) or complete loss of CD38 expression due to antigen escape.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for CD-38 Immunohistochemistry?

• Experienced Healthcare Professionals: Our pathology department is led by highly qualified consultant pathologists specializing in hematopathology and oncological surgical pathology.
• Patient-Focused Care: We prioritize patient comfort, clear communication, and compassionate care throughout the diagnostic journey.
• Quality Diagnostic Services: Lahore PCR Lab adheres to strict internal and external quality assurance protocols to ensure international standards of diagnostic accuracy.
• Professional Reporting: Our reports provide detailed semi-quantitative scoring and comprehensive pathological interpretations to guide clinical decision-making.
• Modern Diagnostic Approach: We utilize advanced automated immunohistochemistry staining platforms that minimize manual errors and optimize staining quality.
• Comfortable Environment: Our sample collection centers in Lahore are designed to provide a clean, safe, and comfortable experience for patients undergoing blood draws or biopsy submissions.
• Convenient Location: Located centrally in Lahore, our laboratory is easily accessible to patients and medical couriers from all parts of the city.
• Commitment to Accurate Diagnosis: We understand the critical nature of cancer diagnostics and are dedicated to delivering precise, evidence-based results that physicians can trust.